[go: up one dir, main page]

MX2016008131A - Compuestos heterociclos biciclicos y sus usos en terapia. - Google Patents

Compuestos heterociclos biciclicos y sus usos en terapia.

Info

Publication number
MX2016008131A
MX2016008131A MX2016008131A MX2016008131A MX2016008131A MX 2016008131 A MX2016008131 A MX 2016008131A MX 2016008131 A MX2016008131 A MX 2016008131A MX 2016008131 A MX2016008131 A MX 2016008131A MX 2016008131 A MX2016008131 A MX 2016008131A
Authority
MX
Mexico
Prior art keywords
therapy
bicyclic heterocycle
heterocycle compounds
compounds
cancer
Prior art date
Application number
MX2016008131A
Other languages
English (en)
Other versions
MX380469B (es
Inventor
Steven Howard
Christopher Norbert Johnson
Ildiko Maria Buck
Gianni Chessari
Emiliano Tamanini
James Edward Harvey Day
Charlotte Mary Griffiths-Jones
Saxty Gordon
Elisabeth Wilsher Nicola
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1322755.8A external-priority patent/GB201322755D0/en
Priority claimed from GB201406986A external-priority patent/GB201406986D0/en
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of MX2016008131A publication Critical patent/MX2016008131A/es
Publication of MX380469B publication Critical patent/MX380469B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)

Abstract

La invención se refiere a nuevos compuestos heterociclos bicíclicos, a composiciones farmacéuticas que comprenden dichos compuestos y al uso de dichos compuestos en el tratamiento de enfermedades, por ejemplo, cáncer.
MX2016008131A 2013-12-20 2014-12-19 Compuestos heterociclos bicíclicos y sus usos en terapia. MX380469B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322755.8A GB201322755D0 (en) 2013-12-20 2013-12-20 Bicyclic heterocycle compounds and their uses in therapy
GB201406986A GB201406986D0 (en) 2014-04-17 2014-04-17 Bicyclic heterocycle compounds and their uses in therapy
PCT/GB2014/053778 WO2015092420A1 (en) 2013-12-20 2014-12-19 Bicyclic heterocycle compounds and their uses in therapy

Publications (2)

Publication Number Publication Date
MX2016008131A true MX2016008131A (es) 2016-09-16
MX380469B MX380469B (es) 2025-03-12

Family

ID=52134239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008131A MX380469B (es) 2013-12-20 2014-12-19 Compuestos heterociclos bicíclicos y sus usos en terapia.

Country Status (29)

Country Link
US (6) US9783538B2 (es)
EP (2) EP3083616B1 (es)
JP (3) JP6470756B2 (es)
KR (1) KR102408262B1 (es)
CN (3) CN115368356B (es)
AU (2) AU2014369446C1 (es)
BR (2) BR112016014561B1 (es)
CA (1) CA2933939C (es)
CY (1) CY1124436T1 (es)
DK (1) DK3083616T3 (es)
ES (1) ES2883289T3 (es)
HR (1) HRP20211406T1 (es)
HU (1) HUE056297T2 (es)
IL (1) IL246239B (es)
LT (1) LT3083616T (es)
MX (1) MX380469B (es)
MY (2) MY193649A (es)
NZ (2) NZ719905A (es)
PH (1) PH12016501139A1 (es)
PL (1) PL3083616T3 (es)
PT (1) PT3083616T (es)
RS (1) RS62301B1 (es)
RU (1) RU2696310C1 (es)
SA (1) SA516371360B1 (es)
SG (2) SG11201604795RA (es)
SI (1) SI3083616T1 (es)
SM (1) SMT202100497T1 (es)
TW (1) TWI649319B (es)
WO (1) WO2015092420A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
DK3083616T3 (da) * 2013-12-20 2021-08-30 Astex Therapeutics Ltd Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US10940127B2 (en) 2015-11-25 2021-03-09 Io Therapeutics, Inc. Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
KR20180120208A (ko) * 2016-02-24 2018-11-05 칠드런스 하스피탈 오브 이스턴 온타리오 리서치 인스티튜트 인코포레이티드 암을 치료하기 위한 smc 조합 요법
CN109311867A (zh) 2016-04-20 2019-02-05 葛兰素史克知识产权开发有限公司 包含ripk2抑制剂的共轭物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2017214575A1 (en) 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
JP2020526539A (ja) 2017-07-13 2020-08-31 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せた受容体サブタイプ及び機能に選択性を示すレチノイド及びレキシノイド化合物
KR20200044889A (ko) 2017-08-31 2020-04-29 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제
WO2020148447A1 (en) 2019-01-17 2020-07-23 Debiopharm International S.A. Combination product for the treatment of cancer
WO2020206137A1 (en) 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CN114727984A (zh) 2019-09-25 2022-07-08 德彪药业国际股份公司 治疗患有局部晚期鳞状细胞癌的患者的给药方案
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN115989212B (zh) * 2020-05-04 2025-08-29 大塚制药株式会社 用于合成无水乳酸的方法
WO2021225955A1 (en) * 2020-05-04 2021-11-11 Astex Pharmaceuticals, Inc. Iap antagonist compounds and intermediates and methods for synthesizing the same
US20230219975A1 (en) 2020-06-04 2023-07-13 Beigene, Ltd. Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as iap antagonists
JP7741169B2 (ja) * 2020-08-12 2025-09-17 アーチャー－ダニエルズ－ミッドランド カンパニー ２，５－フランジカルボン酸ジメチルエステル、及びその他のエステル化生成物の精製
AU2021333983A1 (en) 2020-08-27 2023-01-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using MDM2 antagonists
PE20231555A1 (es) * 2020-09-14 2023-10-03 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CA3229750A1 (en) 2021-08-20 2023-02-23 Otsuka Pharmaceutical Co., Ltd. Combination drug
KR20240132251A (ko) * 2021-10-22 2024-09-03 유니버시티 오브 휴스턴 시스템 상피 조직의 만성 염증성 손상, 화생, 이형성증 및 암을 치료하기 위한 방법 및 조성물
JP7777679B2 (ja) * 2021-11-05 2025-11-28 ハイファ バイオファーマ カンパニー リミテッド 固体分散体、その製造方法及びそれを含む固形製剤
US20250186451A1 (en) 2022-03-04 2025-06-12 Otsuka Pharmaceutical Co., Ltd. Methods of treating cancer with iap antagonist compounds and combination therapies
EP4529455A1 (en) 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用
CN116375700B (zh) * 2023-01-10 2024-12-17 中国科学院成都生物研究所 一种4-氮杂吲哚啉类化合物及其合成方法与应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
TW202510888A (zh) 2023-07-31 2025-03-16 日商大塚製藥股份有限公司 包含托利那泮(tolinapant)之醫藥組合物及包裝
WO2025235719A1 (en) * 2024-05-08 2025-11-13 Viiv Healthcare Company Dimeric smac mimetics useful in hiv therapy

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
TW218875B (es) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
ATE243697T1 (de) 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivate als crf antagonisten
AU2056197A (en) 1996-02-22 1997-09-10 Du Pont Merck Pharmaceutical Company, The M-amidino phenyl analogs as factor xa inhibitors
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
TR199902590T2 (xx) 1997-04-18 2000-06-21 Smithkline Beecham P.L.C. Birle�ik 5HT1A 5HT1B ve 5HT1D resept�r antagonist aktivitesi olan indol t�revleri.
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
HUP0100926A3 (en) 1998-02-26 2003-03-28 Neurogen Corp Branford Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU762726B2 (en) 1998-03-31 2003-07-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
ES2276530T3 (es) 1998-08-26 2007-06-16 Aventis Pharma Limited Azabiciclos qu4e modelan la inhibicion de la adherencia celular.
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
US6790845B2 (en) 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
EP1498125A4 (en) 2002-04-24 2008-08-20 Takeda Pharmaceutical USE OF COMPOUNDS WITH CCR ANTAGONISM
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
CN100516040C (zh) 2003-03-07 2009-07-22 安斯泰来制药有限公司 具有2,6-二取代苯乙烯基的含氮杂环衍生物
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2007502287A (ja) 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
BRPI0509721A (pt) 2004-04-07 2007-09-25 Novartis Ag inibidores de iap
NZ588799A (en) 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
DE602005022936D1 (de) 2004-12-20 2010-09-23 Genentech Inc Pyrrolidine als inhibitoren von iap
WO2006091972A2 (en) 2005-02-25 2006-08-31 Tetralogic Pharmaceuticals Dimeric iap inhibitors
KR20080067697A (ko) 2005-11-11 2008-07-21 에프. 호프만-라 로슈 아게 응고 인자 ｘａ의 억제제로서 카보사이클릭 융합된사이클릭 아민
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
US20100016340A1 (en) 2006-04-25 2010-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2008014252A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CN101595121A (zh) 2006-10-12 2009-12-02 诺瓦提斯公司 作为iap抑制剂的吡咯烷衍生物
WO2008073305A1 (en) 2006-12-07 2008-06-19 Novartis Ag 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
WO2009067233A1 (en) 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
KR20100119768A (ko) 2008-01-24 2010-11-10 테트랄로직 파마슈티칼스 코포레이션 아이에이피 억제제
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
JP5628841B2 (ja) 2009-02-27 2014-11-19 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビター
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
EA201171415A1 (ru) 2009-05-28 2013-01-30 Тетралоджик Фармасьютикалз Корп. Ингибиторы белков семейства iap
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
WO2013052110A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
DK3083616T3 (da) 2013-12-20 2021-08-30 Astex Therapeutics Ltd Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
EP3091984B1 (en) 2014-01-09 2020-04-22 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Substituted benzoxazine and related compounds
CN115989212B (zh) 2020-05-04 2025-08-29 大塚制药株式会社 用于合成无水乳酸的方法
WO2021225955A1 (en) 2020-05-04 2021-11-11 Astex Pharmaceuticals, Inc. Iap antagonist compounds and intermediates and methods for synthesizing the same
US20250186451A1 (en) 2022-03-04 2025-06-12 Otsuka Pharmaceutical Co., Ltd. Methods of treating cancer with iap antagonist compounds and combination therapies
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Also Published As

Publication number Publication date
US20170029419A1 (en) 2017-02-02
US12202828B2 (en) 2025-01-21
RU2696310C1 (ru) 2019-08-01
IL246239A0 (en) 2016-08-02
SG10201808102WA (en) 2018-10-30
SMT202100497T1 (it) 2021-09-14
CN109336883A (zh) 2019-02-15
MY193649A (en) 2022-10-21
NZ758528A (en) 2022-05-27
BR112016014561A2 (es) 2017-08-08
KR20160095160A (ko) 2016-08-10
RU2016129472A (ru) 2018-01-25
US11643410B2 (en) 2023-05-09
US11225476B2 (en) 2022-01-18
AU2019200840B2 (en) 2020-05-28
US20180065959A1 (en) 2018-03-08
SA516371360B1 (ar) 2019-02-10
KR102408262B1 (ko) 2022-06-10
CN105829310A (zh) 2016-08-03
US20230227450A1 (en) 2023-07-20
MY186311A (en) 2021-07-08
CA2933939C (en) 2021-03-16
CN115368356A (zh) 2022-11-22
EP3083616A1 (en) 2016-10-26
IL246239B (en) 2019-08-29
NZ719905A (en) 2019-10-25
US10618895B2 (en) 2020-04-14
PH12016501139B1 (en) 2016-07-18
CN115368356B (zh) 2025-05-09
RS62301B1 (sr) 2021-09-30
SG11201604795RA (en) 2016-07-28
CY1124436T1 (el) 2022-07-22
US20220204503A1 (en) 2022-06-30
HRP20211406T1 (hr) 2021-12-10
DK3083616T3 (da) 2021-08-30
AU2019200840A1 (en) 2019-02-28
US9783538B2 (en) 2017-10-10
ES2883289T3 (es) 2021-12-07
LT3083616T (lt) 2021-09-10
AU2014369446A1 (en) 2016-06-02
TWI649319B (zh) 2019-02-01
JP7110279B2 (ja) 2022-08-01
SI3083616T1 (sl) 2021-12-31
PH12016501139A1 (en) 2016-07-18
BR122022015241B1 (pt) 2023-09-26
AU2014369446B2 (en) 2018-11-22
CN109336883B (zh) 2022-06-14
JP6735369B2 (ja) 2020-08-05
PT3083616T (pt) 2021-08-12
CA2933939A1 (en) 2015-06-25
JP6470756B2 (ja) 2019-02-13
MX380469B (es) 2025-03-12
WO2015092420A1 (en) 2015-06-25
JP2017500338A (ja) 2017-01-05
EP3083616B1 (en) 2021-06-09
EP3686200A3 (en) 2020-09-09
JP2019070030A (ja) 2019-05-09
JP2020183409A (ja) 2020-11-12
CN105829310B (zh) 2019-04-12
AU2014369446C1 (en) 2020-03-12
US20200325134A1 (en) 2020-10-15
TW201609724A (zh) 2016-03-16
BR112016014561B1 (pt) 2022-10-18
US20250296930A1 (en) 2025-09-25
HUE056297T2 (hu) 2022-02-28
PL3083616T3 (pl) 2021-12-06
EP3686200A2 (en) 2020-07-29
AU2019200840C1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2017013556A (es) Compuestos novedosos.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
MX378273B (es) Compuestos activos hacia bromodominios.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
UY35747A (es) Derivados sustituidos de fenilalanina
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso